Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

teriflunomide

- PMLiVE

Sanofi/Regeneron’s alirocumab ‘cuts cardiovascular events’

Data presented at ESC Congress demonstrates lower rates of cardiac death, stroke and more

Biogen Idec building

Final NICE backing for Biogen Idec’s Tecfidera

Oral multiple sclerosis is cleared for NHS use in England

- PMLiVE

FDA gives green light to Genzyme’s oral Gaucher drug

Oral therapy Cerdelga is set to complement intravenous Cerezyme

- PMLiVE

Illumina partners with pharma majors on cancer diagnostic

Will work with AstraZeneca, Janssen and Sanofi to develop gene sequencing tool

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

Biogen Idec building

FDA approves Biogen Idec’s long-acting MS therapy

Plegridy gets US nod just weeks after EU approval

- PMLiVE

Rebif hit again as competition bites

Merck Serono’s MS drug continues its struggle for sales in the US and Europe

- PMLiVE

Sanofi ships synthetic malaria jab

French manufacturer says Gates Foundation-funded venture could widen treatment

- PMLiVE

Sanofi cuts $925m deal for MannKind’s inhaled insulin

French company bolsters diabetes business with Afrezza collaboration

MS market set to grow 4% annually

Predictedto reach $20bn by 2023 partly due to Plegridy and ocrelizumab launches

Sanofi reception

Sanofi asks Emcure to sell its cancer drugs in India

Will hand over marketing of Taxotere, Jevtana, Fludara and Fasturtec

Sanofi reception

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Buy FDA priority review voucher from BioMarin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links